Preview

Остеопороз и остеопатии

Расширенный поиск

ЗОЛЕДРОНОВАЯ КИСЛОТА В ПРОФИЛАКТИКЕ ПОТЕРИ КОСТНОЙ ТКАНИ У жЕНЩИН ПОСТМЕНОПАУЗАЛЬНОГО ВОЗРАСТА С ОСТЕОПЕНИЕЙ

https://doi.org/10.14341/osteo2011237-39

Аннотация

Список литературы

1. Miller R.G. Osteoporosis in postmenopausal women. Therapy options across a wide range of risk for fracture. Geriatrics 2006;61: 24-30.

2. Brown J.P., Josse R.G., 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada [published errata appear in CMAJ 2003; 168: 400, CMAJ 2003; 168: 676, and CMAJ 2003; 168: 544]. CMAJ. 2002;167 (10 Suppl): S1-34.

3. Siris E.S., Miller P.D., Barrett-Connor E., Faulkner K.G., Wehren L.E., Abbott T.A., et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 2001; 286: 2815-22.

4. National Osteoporosis Foundation 2008. Available at: http://www.nof.org/ professionals/NOF±Clinicians±Guide.pdf. Retrieved July 11, 2009.

5. McClung M., Clemmesen B., Daifotis A., Gilchrist N.L., Eisman J., Weinstein R.S., et al. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. Ann Intern Med 1998; 128: 253-61.

6. McClung M., Siris E., Cummings S., Bolognese M., Ettinger M., Moffett A., et al. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene. Menopause 2006; 13: 377-86.

7. McClung M., Recker R., Miller P., Fiske D., Minkoff J., Kriegman A., et al. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone 2007; 41: 122-8.

8. Boccuzzi S.J., Folz S.H., Omar M.A., Kahler K.H. Assessment of adherence and persistence with daily and weekly dosing regimens of oral bisphosphonates. Osteoporos Int 2005; 16 (Suppl 4): S35-6.

9. Black D.M., Delmas P.D., Eastell R., Reid I.R., Boonen S., Cauley J.A., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809-22.

10. Lyles K.W., Colo'n-Emeric C.S., Magaziner J.S., Adachi J.D., Pieper C.F., Mautalen C., et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007; 357: 1799-809

11. Reid I.R., Brown J.P., Burckhardt P., Horowitz Z., Richardson P., Trechsel U., et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002; 346: 653-61.

12. Boivin G.Y., Chavassieux P.M., Santora A.C., Yates J., Meunier P.J. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 2000; 27: 687-94.

13. Reginster J.Y., Collette J., Neuprez A., Zegels B., Deroisy R., Bruyere O. Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy. Bone 2008; 42: 832-6.

14. Borah B., Dufresne T.E., Ritman E.L., Jorgensen S.M., Liu S., Chmielewski P.A., et al. Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with microcomputed tomography. Bone 2006; 39: 345-52

15. Sornay-Rendu E., Munoz F., Garnero P., Duboeuf F., Delmas P.D. Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res 2005; 20: 1813-9.

16. Wainwright S.A., Marshall L.M., Ensrud K.E., Cauley J.A., Black D.M., Hillier T.A., et al. Hip fracture in women without osteoporosis J Clin Endocrinol Metab 2005; 90: 2787-93

17. Menopause and osteoporosis update 2009. http://www.sogc.org/guidelines/ documents/Menopause±JOGC-Jan±09.pdf. Retrieved July 11, 2009.

18. Drake W.M., Kendler D.L., Rosen C.J., Orwoll E.S. An investigation of the predictors of bone mineral density and response to therapy with alendronate in osteoporotic men. J Clin Endocrinol Metab 2003;88: 5759-65.

19. Lenora J., Ivaska K.K., Obrant K.J., Gerdhem P. Prediction of bone loss using biochemical markers of bone turnover. Osteoporos Int 2007;18: 1297-305.

20. Reginster J.Y., Deroisy R., Collete J., Albert A., Zegels B. Prediction of bone loss rate in healthy postmenopausal women. Calcif Tissue Int 1997;60: 261-4.

21. Garnero P., Sornay-Rendu E., Duboeuf F., Delmas P.D. Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: The OFELY study. J Bone Miner Res 1999; 14: 1614-21.

22. Rogers A., Hannon R.A., Eastell R. Biochemical markers as predictors of rates of bone loss after menopause. J Bone Miner Res 2000; 15: 1398-404.

23. Garnero P., Munoz F., Sornay-Rendu E., Delmas P.D. Associations of vitamin D status with bone mineral density, bone turnover, bone loss and fracture risk in healthy postmenopausal women. The OFELY study. Bone 2007; 40: 716-22.

24. McClung M.R. Osteopenia: to treat or not to treat? Ann Intern Med 2005; 142: 796-7.

25. Watts N.B. What is osteopenia, and what should be done about it? Cleve Clin J Med 2006; 73: 29

26. Khosla S., Melton III L.J. Clinical practice. Osteopenia. N Engl J Med 2007; 356: 2293-300.

27. Schousboe J.T., Nyman J.A., Kane R.L., Ensrud K.E. Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med 2005; 142: 734-41.

28. Meadows E.S., Klein R., Rousculp M.D., Smolen L., Ohsfeldt R.L., Johnston J.A. Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia. BMC Womens Health 2007; 7: 6

29. Chen Y.T., Miller P.D., Barrett-Connor E., Weiss T.W., Sajjan S.G., Siris E.S. An approach for identifying postmenopausal women age 50-64 years at increased short-term risk for osteoporotic fracture. Osteoporos Int 2007; 18: 1287-96.

30. Simon J.A. Does osteopenia warrant treatment? Menopause 2005; 12: 639-48.

31. Wasnich R.D., Miller P.D. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 2000; 85: 231-6.


Рецензия

Для цитирования:


, , , , , ЗОЛЕДРОНОВАЯ КИСЛОТА В ПРОФИЛАКТИКЕ ПОТЕРИ КОСТНОЙ ТКАНИ У жЕНЩИН ПОСТМЕНОПАУЗАЛЬНОГО ВОЗРАСТА С ОСТЕОПЕНИЕЙ. Остеопороз и остеопатии. 2011;14(2):37-39. https://doi.org/10.14341/osteo2011237-39

For citation:


Mcclung M., Miller P., Recknor Ch., Mesenbrink P., Bucci-Rechtweg Ch., Benhamou C. ZOLEDRONOVAYa KISLOTA V PROFILAKTIKE POTERI KOSTNOY TKANI U zhENShchIN POSTMENOPAUZAL'NOGO VOZRASTA S OSTEOPENIEY. Osteoporosis and Bone Diseases. 2011;14(2):37-39. (In Russ.) https://doi.org/10.14341/osteo2011237-39

Просмотров: 290


ISSN 2072-2680 (Print)
ISSN 2311-0716 (Online)